Thank You, Deeply

Dear Women & Girls Community,

We are excited to share our plans for the future of women and girls’ coverage at News Deeply.

In January 2018, our Women & Girls page will close as we launch the first of a new set of dedicated platforms
that will allow us to dive deeper into the biggest issues affecting women and girls in the developing world.

This first platform – Women’s Advancement Deeply – will cover the pursuit of economic equality for women,
from securing gender-equal access to financial services, to fighting for property rights and closing the pay gap.

We’ll also be working to launch other dedicated platforms in this space, and we are currently exploring themes
of maternal, sexual and reproductive health, as well as gender-based violence. If these topics are of interest
to you, please let us know here – we would love your input as we shape new initiatives.

Our trove of existing Women & Girls coverage will remain available through an archived version of the site,
allowing you to explore and reference our published articles dating back to May 2016

Thank you for being part of the Women & Girls community. We look forward to having you join us in our new
endeavors in this space.

Concern Over Popular Contraceptive and HIV Vulnerability in South Africa

Recent studies have shown that the three-month injectable contraceptive Depo-Provera might make people more vulnerable to contracting HIV. In South Africa, where more than 7 million people are infected with HIV, the injectable is the most commonly used contraceptive.

A sign warns pregnant women about HIV at the Askham community health care clinic in the Kalahari, Northern Cape, South Africa. Paballo Thekiso/AFP

CAPETOWN, South Africa – The most popular form of contraception in South Africa may be linked to an increased vulnerability to HIV infection, but health professionals have no guidance on what to do about it.

In a country where more than 22 percent of women aged 15-49 are HIV positive, the potential link is cause for concern among providers. The three-month injectable contraceptive, sold under the Depo-Provera brand, is provided for free by the South African government.

The latest Demographic and Health Survey showed 17.7 percent of South African women are using it. If there were a causal link between Depo-Provera and increased vulnerability to HIV, these numbers would put millions of women at risk. However, a such a link has yet to be definitively proven.

One recent study, from the Population Research Institute, showed Depo-Provera increased women’s risk of acquiring HIV by 49 percent when compared with women who did not use hormonal contraception. But other studies have not shown the same increase.

The differing results have caused confusion among healthcare providers, so in December 2016 the World Health Organisation Guidance Group, made up of scientists and researchers from around the world, reviewed 13 observational studies that showed the potential risk of increased HIV vulnerability when using Depo-Provera.

Their guidance note, issued this year, expresses concern and recommends women be told about a possible increased risk. It does not, however, suggest the withdrawal of Depo-Provera.

“For many women, Depo-Provera has been a godsend.”

In South Africa, health professionals explain the popularity of Depo-Provera by the ease of its use: It is more convenient than taking a daily pill, it requires less frequent clinic visits and no supplies need to be kept at home.

“For many women, Depo-Provera has been a godsend,” says Marion Stevens, chairperson of the Sexual and Reproductive Justice Coalition. “But the challenge is that there is no policy position [in South Africa] on what to say about these potential risks.”

If women are not able to use Depo-Provera, the other options are a two-month injectable, the contraceptive pill or the contraceptive implant. But not all of these methods are equally available at all facilities.

Professor Helen Rees, executive director of the WITS Reproductive Health and HIV Institute, says that early observational studies conducted in the late 2000s looking at HIV and the three-month injectable weren’t consistent.

“Some have shown increased risk and some have not,” she says. “You’ve also got problems with the methodology.” She says these studies were focused on other research – such as the efficacy of various microbicides – and not on Depo-Provera exclusively.

“The observational data as it stands at the moment tends to suggest an increased risk with Depo-Provera when compared with other hormonal methods.”

In addition, they were not able to isolate for all variables, for example whether the participants changed to different forms of contraception during the study.

Since then several studies have been better designed and Rees says that “the observational data as it stands at the moment tends to suggest an increased risk with Depo-Provera when compared with other hormonal methods.”

Now, scientists are trying to find a definitive answer as to why or if Depo-Provera puts women at increased risk of HIV contraction.

The study is being undertaken at 12 sites in four countries (Kenya, South Africa, Swaziland and Zimbabwe) and looks at Depo-Provera, a two-year implant called Jadelle and copper intrauterine devices (IUDs) – which are not based on hormones.

“The women who are enrolled are HIV-negative women who are seeking contraception, are sexually active and are happy to be enrolled in one of these three methods,” Rees explains.

These women receive counseling to make sure they understand the goals of the study and the benefits and risks associated with each method. They are asked to continue on the method for a minimum of 12 months, and up to 18 months.

The early results of the ECHO Trial will only be released in late 2018 or early 2019. Until then, women in South Africa will still be able to opt for Depo-Provera at their local health clinics. Given the number of South African women using Depo-Provera as a preferred method, removing it as an option while the trial is underway could put many women at risk of unwanted pregnancy.

Until the results of the ECHO Trial are out, there is no evidence that getting a Depo-Provera injection increases a woman’s risk of contracting HIV, but the observational studies are cause for concern.

“At the very least, women must be given information to enable real informed consent.”

This puts doctors in a difficult predicament. For Dr. Tlaleng Mofokeng, a reproductive rights activist, the crux of the matter is that women should have access to the latest and best information about contraception and be able to use their preferred option.

“At the very least, women must be given information to enable real informed consent,” she says.

This is why, Mofokeng says – like the World Health Organisation’s 2017 guidance note – women should be advised of the potential links between Depo-Provera and HIV, even before the results of the ECHO Trial are out.

Never miss an update.

Republish this article

Our mission is to empower stakeholders and the wider public with high quality information, insights, and analysis on critical global issues. To help achieve this, we encourage you to republish the text of any article that contains a Republish button on your own news outlet.

By copying the HTML below, you agree to adhere to our republishing guidelines.

By copying the HTML below, you agree to adhere to our republishing guidelines. Click to expand

We simply ask that you:

Ensure that you include a line of our HTML tracking code on every article you republish. This is a lightweight, efficient way for us to see the number of page views of each specific article published on our partners’ websites. This does not affect page layout, nor does it provide any information about your users, other web pages on your site, or any further data. By copying and pasting the HTML code in the box below, the tracking code is automatically included.

If, for any reason, you do not copy the code prepared for you, please paste this code snippet into the end of the article in your CMS:

Note at the top and/or bottom of the story that it originally appeared on Women and Girls. This note should include a direct link to the original article. Also please include a sentence that offers the reader the opportunity to join the Women and Girls’s mailing list.

This should read : “This article originally appeared on Women and Girls. You can find the original here. For important news about gender issues in the developing world, you can sign up to the Women and Girls email list.”

If you want to republish a photo, contact us. Some sources don't allow their images to be republished without permission.

If you'd like to translate a story into another language, contact us.

We often republish pieces from our partners. If you want to republish a partner’s story, please credit the original partner and include a “via News Deeply” link.

Note that News Deeply considers the publication date to be the date marked on the story, and is not responsible for any content that you choose to repost.

After republication on the partner website, please mention the relevant Deeply social media handle in your social promotion, such as @SyriaDeeply, @WaterDeeply, @WomenGirlsHub on Twitter or tag the appropriate site’s Facebook page.

News Deeply material should not to be provided, in whole or in part, directly or indirectly, to third parties or affiliates for redistribution through those entities, unless prior approval has been obtained from News Deeply in writing.

You may not automatically or systematically republish all or the majority of our material from our sites; all stories must be chosen individually.

You may not sell our content or republish it for commercial purposes.

We reserve the right to request that any partner ceases republication of our content, including but not limited to if the guidelines listed above not being followed.

If you have any questions or concerns please contact community@newsdeeply.com